Dexamethasone
Mechanism of action: Dexamethasone is a corticosteroid exhibiting both anti-inflammatory and anti-emetic properties. It prevents the functions of phospholipase A2 and thereby causing anti-inflammatory action. It also interferes in the function of mediators of inflammatory response, and causes suppression of immune responses.
Indication:
Pharmacokinetics: Dexamethasone is readily absorbed from the gastro-intestinal tract. It extensively binds to plasma proteins, mainly to globulin. It is metabolized mainly in the liver but also in the kidney. It is excreted in the urine and has a t1/2 of approximately 190 minutes.
Sonexa 4 tablet is indicated for the pretreatment for chemotherapy to reduce delayed inflammation and side effects associated with chemotherapy. It is indicated for the prevention of nausea and vomiting associated with Cisplatin based highly emetogenic chemotherapy, and moderately emetogenic chemotherapy and combinations of Anthracycline and Cyclophosphamide.
Side effect:
Gastro-intestinal: Dyspepsia, nausea, peptic ulceration, abdominal distension, abdominal pain, diarrhoea, oesophageal ulceration, oesophageal candidiasis and acute pancreatitis. Musculoskeletal: Proximal myopathy and osteoporosis. Endocrine: Suppression of the hypothalamo-pituitary adrenal axis; growth suppression in infancy, childhood and adolescence; menstrual irregularity; amenorrhoea and cushingoid faces. Nervous system: Depression, insomnia and dizziness. Eye disorders: Increased intra-ocular pressure and glaucoma. Immunosuppressive effects: Increased susceptibility to and severity of infections.
Dosage and Administration
The recommended dosage of Sonexa 4 tablet is as following table for the prevention of delayed inflammation and side effects associated with chemotherapy:
Cisplatin-based highly emetogenic cancer chemotherapy –
| Day 1 |
|
||||
| Dexamethasone | 20 mg; 30 min prior to chemotherapy. |
|
|||
| Rolapitant | 180 mg; Approximately 1-2 hours prior to chemotherapy. | None | |||
| 5-HT3 receptorantagonist. | See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information. | None |
| Day 1 |
|
||||
| Dexamethasone | 20 mg; 30 min prior to chemotherapy. | None | |||
| Rolapitant | 180 mg; Approximately 1-2 hours prior to chemotherapy. | None | |||
| 5-HT3 receptorantagonist. | See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information. |
Reviews
There are no reviews yet.